fintepla
ucb pharma s.a. - fenfluramine hydrochloride - epilepsies, myoclonic - antiepileptika, - treatment of seizures associated with dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older. fintepla is indicated for the treatment of seizures associated with dravet syndrome and lennox-gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.
enspryng
roche registration gmbh - satralizumab - neuromyelitis optica - immunosuppressiva - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.
adtralza
leo pharma a/s - tralokinumab - dermatitis, atopisk - andre dermatologiske præparater - adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.
livtencity
takeda pharmaceuticals international ag ireland branch - maribavir - cytomegalovirusinfektioner - antivirale midler til systemisk anvendelse - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). det bør overvejes at officielle vejledning om hensigtsmæssig brug af antivirale agenter.
teriflunomide mylan
mylan pharmaceuticals limited - teriflunomide - multipel sklerose, recidiverende-remitterende - immunosuppressiva - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).
rayvow
eli lilly nederland b.v. - lasmiditan succinate - migræneforstyrrelser - analgetika - rayvow is indicated for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.
spevigo
boehringer ingelheim international gmbh - spesolimab - psoriasis - immunosuppressiva - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.
aquipta
abbvie deutschland gmbh & co. kg - atogepant - migræneforstyrrelser - aquipta is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.
jaypirca
eli lilly nederland b.v. - pirtobrutinib - lymfom, mantelcelle - protein kinase hæmmere - treatment of mantle cell lymphoma (mcl).
adcirca (previously tadalafil lilly)
eli lilly nederland b.v. - tadalafil - hypertension, lunge - urologicals - adultstreatment of pulmonary arterial hypertension (pah) classified as who functional class ii and iii, to improve exercise capacity (see section 5. effektivitet er blevet vist i idiopatisk pah (ipah) og i pah relateret til kollagenvaskulær sygdom. paediatric populationtreatment of paediatric patients aged 2 years and above with pulmonary arterial hypertension (pah) classified as who functional class ii and iii.